Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albutrepenonacog alfa - CSL Behring

Next Previous
Search
Drug Profile

Albutrepenonacog alfa - CSL Behring

Alternative Names: Albumin fusion protein - CSL Behring; CSL 640; CSL-654; Factor IX (Recombinant) - CSL; Idelvion; Recombinant coagulation factor IX - CSL Behring; Recombinant factor IX - CSL Behring; Recombinant factor IX fusion protein linked with human albumin; rFIX-FP - CSL Behring; rIX-FP

Latest Information Update: 26 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Albumins; Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 28 Jun 2024 Phase-III clinical trials in Haemophilia B (Treatment-experienced, In the elederly, In adults, In children) in China (IV) (NCT06399289)
  • 03 May 2024 CSL Behring plans a phase III trial for Haemophilia B (Treatment-experienced) in China in June 2024 (IV) (NCT06399289) (EudraCT2022-002333-34)
  • 02 Jun 2021 CSL Behring completes a phase III trial for Haemophilia B in Australia, Austria, Bulgaria, Canada, Czech Republic, Italy, France, Germany, Japan, Israel, Malaysia, Philippines, South Africa, Spain and USA (IV) (NCT02053792)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top